A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Completed · Phase 2 · Has a placebo group
Conditions studied: Systemic Lupus Erythematosus
In brief
To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).
Key facts
- Study ID
- NCT01283139
- Run by
- MedImmune LLC
- People needed
- 834
- Starts
- 2011-03-31
- Expected to finish
- 2014-04-17
- Last updated by the study team
- 2018-04-19
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Palm Desert, California, United States
- Research Site — San Leandro, California, United States
- Research Site — Fort Lauderdale, Florida, United States
- Research Site — Orlando, Florida, United States
- Research Site — Stockbridge, Georgia, United States
- Research Site — Idaho Falls, Idaho, United States
- Research Site — Shreveport, Louisiana, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Lansing, Michigan, United States
- Research Site — Brooklyn, New York, United States
- Research Site — Manhasset, New York, United States
- Research Site — New York, New York, United States
- Research Site — Charlotte, North Carolina, United States
- Research Site — Raleigh, North Carolina, United States
- Research Site — Dallas, Texas, United States
- Research Site — Seattle, Washington, United States
- Research Site — Buenos Aires, Argentina
- Research Site — Ciudad Autonoma de Buenos Aire, Argentina
- Research Site — Ciudad de Buenos Aires, Argentina
- Research Site — La Plata, Argentina
- Research Site — Quilmes, Argentina
- Research Site — San Miguel de Tucumán, Argentina
- Research Site — Curitiba, Brazil
- Research Site — Goiânia, Brazil
- Research Site — La Jolla, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.